Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001635853
Ethics application status
Approved
Date submitted
19/10/2021
Date registered
29/11/2021
Date last updated
12/07/2023
Date data sharing statement initially provided
29/11/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Flexible Bronchoscopy Insufflated and High-Flow Nasal Oxygen Pilot Trial in Children
Scientific title
Flexible Bronchoscopy Insufflated and High-Flow Nasal Oxygen Pilot Trial in Children
Secondary ID [1] 305574 0
Nil Known
Universal Trial Number (UTN)
U1111-1270-5316
Trial acronym
BUFFALO Pilot Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypoxemia during Flexible Bronchoscopy 323989 0
Condition category
Condition code
Anaesthesiology 321489 321489 0 0
Anaesthetics
Respiratory 321490 321490 0 0
Other respiratory disorders / diseases
Surgery 321491 321491 0 0
Other surgery

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Intervention: High flow nasal oxygen insufflation

Description: High-Flow Nasal Oxygen Insufflation (HFNOI) is insufflation of heated (37 degrees Celsius) and humidified (100%) oxygen at weight-related flow rates matching peak inspiratory flow thereby allowing a known inspired fraction of inspired oxygen.

HFNOI will be delivered during the bronchoscopy via the Optiflow™ device at weight-specific flow rates as per the table below delivering a FiO2 of 1.0.

Weight HFNOI Flow rates
0-12 kg 2L/kg/min
13-15kg 30L/min
15-30 kg 35L/min
30-50 kg 40L/min
>50 kg 50L/min

Jaw thrust will be applied to ensure a patent airway until airway instrumentation begins.
Anaesthesia will be maintained via a Total Intravenous Venous Anaesthesia (TIVA) using a combination of dexmedetomidine, propofol +/- an opioid (either remifentanil or alfentanil) at the discretion of the attending anaesthetist. Anaesthetists may wish to omit opioids in certain circumstances and this will be at the discretion of the anaesthetist e.g. neonates. Anaesthesia infusions will be adjusted to maintain both adequate depth of anaesthesia and spontaneous ventilation during the procedure. TIVA is used because inhalation agents can not be delivered when using HFNOI, TIVA is not the intervention of interest.
The adherence to the intervention will be monitored by the research assistant present in the room collecting data and recorded on a case report form.
Intervention code [1] 321969 0
Treatment: Devices
Intervention code [2] 321970 0
Prevention
Comparator / control treatment
Standard facemask /LMA technique

Description: Oxygen insufflation will be at a flow rate of up to 6L/min via an anaesthesia facemask or LMA as per local hospital policy or practices . Anaesthesia will be maintained at the discretion of the anaesthetist, via inhalational anaesthesia, intravenous agents, or a combination of both. Intravenous agents as per choice of the attending anaesthetist.
The adherence to the intervention will be monitored by the research assistant present in the room collecting data and recorded on a case report form.
Control group
Active

Outcomes
Primary outcome [1] 329266 0
The rate of participant recruitment assessed by completion of screening and enrollment log
Timepoint [1] 329266 0
Screening will occur daily by the research assistant until the recruitment target has been met.
Primary outcome [2] 329451 0
Adherence to the protocol without deviation assessed by completion of case report form completed by the research assistant during the bronchoscopy
Timepoint [2] 329451 0
During the bronchoscopy for children enrolled
Secondary outcome [1] 401957 0
The proportion of children experiencing a hypoxaemic event defined by a oxygen saturation < 90%, within 10% of baseline collected by pulse oximeter data captured during the bronchoscopy
Timepoint [1] 401957 0
Continuous pulse oximetry will be taken during the surgical procedure
Secondary outcome [2] 401958 0
The proportion of children requiring interruption of the procedure to rescue the oxygenation by positive pressure assisted ventilation assessed by observation and completion of case report form completed by the research assistant during the bronchoscopy
Timepoint [2] 401958 0
Continuous observation by the research assistant for the duration of the surgical procedure
Secondary outcome [3] 401959 0
The severity of the hypoxaemic event described by the area under the curve of time below SpO2 of 90% collected by pulse oximeter data captured during the bronchoscopy
Timepoint [3] 401959 0
Continuous pulse oximetry will be taken during the surgical procedure
Secondary outcome [4] 401960 0
Significant adverse events requiring treatment will be graded using the CTCAE5.
AEs for this study are defined as:
*Hypoxaemia leading to cardiac massage
*Cardiac arrest: Loss of spontaneous cardiac output
*Mortality
*OR any life-threatening medical event or reaction which the clinician believes may be study-related
*Hypotension: requiring treatment with fluid and/or vasoconstrictors
*Bradycardia of <60/min or < 40 if older than 6 years
Timepoint [4] 401960 0
Continuous observation by the research assistant for the duration of the surgical procedure

Eligibility
Key inclusion criteria
* 0 (>37 weeks gestational age) – 16 years of age (15 years + 364 days)
• Elective flexible bronchoscopy
*Clinicians approval for inclusion
Minimum age
0 Weeks
Maximum age
16 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Known choanal atresia
• HFNOI contraindication (recent cranial and/or mid-face surgery/trauma; CSF leak)
• Emergency airway cases out of hours (after hours during week and weekend)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation via computer will be used to achieve allocation concealment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Patients will be allocated to a treatment arm using a computer based randomisation schedule and an allocation of 1:1 per treatment arm. Randomisation will be stratified by age (<1 year, 1-5 year and 5-16 year of age), with randomly varied block sizes within each stratum.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
Descriptive statistics will be used to report on the baseline characteristics of the total study cohort and each treatment group, as well as by site. As this is a pilot trial, formal statistical comparisons will not be undertaken. All outcomes will be presented as estimates along with 95% confidence interval (CI); feasibility outcomes will be presented only for the total cohort, while safety and efficacy outcomes will be presented for the total cohort, as well as per treatment group. Analyses will be undertaken using intention-to-treat, however the number and type of protocol deviations will be reported to assist in feasibility assessment.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/02/2022
Actual
3/05/2022
Date of last participant enrolment
Anticipated
1/12/2023
Actual
Date of last data collection
Anticipated
31/12/2023
Actual
Sample size
Target
80
Accrual to date
58
Final
Recruitment in Australia
Recruitment state(s)
QLD,WA
Recruitment hospital [1] 20775 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [2] 20776 0
Perth Children's Hospital - Nedlands
Recruitment postcode(s) [1] 35586 0
4101 - South Brisbane
Recruitment postcode(s) [2] 35587 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 309935 0
Hospital
Name [1] 309935 0
Queensland Children's Hospital
Country [1] 309935 0
Australia
Primary sponsor type
University
Name
University of Queensland
Address
288 Herston Road
Herston QLD 4006, Australia
Country
Australia
Secondary sponsor category [1] 310975 0
None
Name [1] 310975 0
Address [1] 310975 0
Country [1] 310975 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309654 0
Human Research Ethics Committee Centre for Children’s Health Research
Ethics committee address [1] 309654 0
Ethics committee country [1] 309654 0
Australia
Date submitted for ethics approval [1] 309654 0
11/10/2021
Approval date [1] 309654 0
17/11/2021
Ethics approval number [1] 309654 0
HREC/21/QCHQ/76582

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 114918 0
A/Prof Susan Humphreys
Address 114918 0
Centre for Children's Health Research
Level 7
62 Graham St
South Brisbane
QLD, 4101
Country 114918 0
Australia
Phone 114918 0
+617 3069 7480
Fax 114918 0
Email 114918 0
[email protected]
Contact person for public queries
Name 114919 0
Susan Humphreys
Address 114919 0
Centre for Children's Health Research
Level 7
62 Graham St
South Brisbane
QLD, 4101
Country 114919 0
Australia
Phone 114919 0
+617 3069 7480
Fax 114919 0
Email 114919 0
[email protected]
Contact person for scientific queries
Name 114920 0
Susan Humphreys
Address 114920 0
Centre for Children's Health Research
Level 7
62 Graham St
South Brisbane
QLD, 4101
Country 114920 0
Australia
Phone 114920 0
+61 7 3069 7480
Fax 114920 0
Email 114920 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified data on a case-by-case basis at the discretion of Principal Investigator A/Prof Susan Humphreys and Primary Sponsor
When will data be available (start and end dates)?
3 months following publication and ending 5 years following main results publication
Available to whom?
De-identified data on a case-by-case basis at the discretion of Principal Investigator A/Prof Susan Humphreys and Primary Sponsor of researchers with a sound proposal
Available for what types of analyses?
De-identified data on a case-by-case basis at the discretion of Principal Investigator A/Prof Susan Humphreys of researchers for secondary analysis with a sound proposal
How or where can data be obtained?
Access subject to approvals by Principal Investigator A/Prof Susan Humphreys [email protected]


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIFlexible bronchoscopy insufflated and high-flow nasal oxygen pilot trial (BUFFALO protocol pilot trial)2024https://doi.org/10.1186/s40814-024-01464-w
N.B. These documents automatically identified may not have been verified by the study sponsor.